NicholasJamesShortMD

PubMed

• Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
  Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
  Haematologica. 2024-12-12
• Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy.
  Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Sa A Wang
  Blood Advances. 2024-12-04
• Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.
  Fadi G Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park
  JCO Oncology Practice. 2024-12-01

Abstracts/Posters

• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA ...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphob...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Nicholas J. Short, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Periphera... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Risk of Atrial Fibrillation with Ibrutinib in Patients with B-Cell Malignancies: An Updated Meta-Analysis of Phase III Randomized Controlled Trials 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all